{
    "url_original": "https://www.wsj.com/articles/china-u-s-tension-mars-biotech-giant-beigenes-shanghai-debut-11639572059?mod=markets_lead_pos3",
    "url": "china-u-s-tension-mars-biotech-giant-beigenes-shanghai-debut-11639572059",
    "title": "China-U.S. Tension Mars Biotech Giant BeiGene’s Shanghai Debut",
    "sub_head": "Goldman-sponsored deal is the largest healthcare IPO of 2021",
    "category_1": "Markets",
    "time": "2021-12-15 07:41:00",
    "body": "Chinese biotechnology firm  BeiGene Ltd.  tumbled 16% in its mainland trading debut, after raising $3.5 billion and becoming the first company to be triple-listed in New York, Hong Kong and on Shanghai’s STAR Market.<br />The most senior banks, or sponsors, for the onshore initial public offering were  China International Capital Corp.  and Goldman Sachs Gao Hua Securities, the Chinese unit of  Goldman Sachs Group Inc.  It is the first IPO to be sponsored by a U.S. bank in China’s domestic A-share market."
}